The stock of Cytosorbents Corp (NASDAQ:CTSO) is a huge mover today! About 379,390 shares traded hands or 313.94% up from the average. Cytosorbents Corp (NASDAQ:CTSO) has risen 33.53% since March 2, 2016 and is uptrending. It has outperformed by 25.27% the S&P500.
The move comes after 9 months negative chart setup for the $148.62M company. It was reported on Oct, 5 by Barchart.com. We have $5.29 PT which if reached, will make NASDAQ:CTSO worth $14.86 million less.
Analysts await Cytosorbents Corp (NASDAQ:CTSO) to report earnings on November, 11. They expect $-0.11 earnings per share, 0.00% or $0.00 from last year’s $-0.11 per share. After $-0.12 actual earnings per share reported by Cytosorbents Corp for the previous quarter, Wall Street now forecasts -8.33% EPS growth.
Cytosorbents Corp (NASDAQ:CTSO) Ratings Coverage
Out of 2 analysts covering CytoSorbents (NASDAQ:CTSO), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. CytoSorbents has been the topic of 2 analyst reports since October 29, 2015 according to StockzIntelligence Inc. Maxim Group initiated it with “Buy” rating and $8 target price in Tuesday, May 24 report. The firm has “Buy” rating given on Thursday, October 29 by WBB Securities.
According to Zacks Investment Research, “CytoSorbents Corporation is a therapeutic medical device company. It develops adsorbent polymer technology for applications in the medical field, primarily to provide blood purification for the treatment of acute and chronic health complications associated with blood toxicity. The Company’s product include CytoSorb, which filters cytokines and treat potentially fatal cytokine storm and BetaSorb, which remove beta2-microglobulin from the blood of patients suffering from chronic kidney failure. CytoSorbents Corporation is headquartered in Monmouth Junction, New Jersey.”
Insitutional Activity: The institutional sentiment decreased to 0.79 in Q2 2016. Its down 0.07, from 0.86 in 2016Q1. The ratio is negative, as 7 funds sold all Cytosorbents Corp shares owned while 7 reduced positions. 4 funds bought stakes while 7 increased positions. They now own 1.36 million shares or 2.40% less from 1.40 million shares in 2016Q1.
Northern Tru holds 0% of its portfolio in Cytosorbents Corp (NASDAQ:CTSO) for 23,709 shares. Ladenburg Thalmann last reported 24,069 shares in the company. Moreover, Blackrock Mngmt Lc has 0% invested in Cytosorbents Corp (NASDAQ:CTSO) for 3,776 shares. Royal National Bank Of Canada has 800 shares for 0% of their US portfolio. Moreover, State Street Corp has 0% invested in Cytosorbents Corp (NASDAQ:CTSO) for 12,000 shares. Deutsche Retail Bank Ag owns 75 shares or 0% of their US portfolio. Barclays Public Ltd Com accumulated 4 shares or 0% of the stock. Fortaleza Asset Mngmt Inc holds 0.07% of its portfolio in Cytosorbents Corp (NASDAQ:CTSO) for 19,625 shares. Raymond James Associate last reported 0% of its portfolio in the stock. Blackrock Advisors Limited Liability Company has 864 shares for 0% of their US portfolio. Tower Ltd Liability (Trc) last reported 694 shares in the company. Pnc Service Grp Incorporated last reported 0% of its portfolio in the stock. Moreover, Jpmorgan Chase And has 0% invested in Cytosorbents Corp (NASDAQ:CTSO) for 2,042 shares. Skylands Capital Ltd Com holds 0.04% of its portfolio in Cytosorbents Corp (NASDAQ:CTSO) for 48,350 shares. Geode Cap Mgmt Limited Liability Company has 0% invested in the company for 125,772 shares.
Insider Transactions: Since June 7, 2016, the stock had 2 insider buys, and 0 selling transactions for $39,090 net activity. On Wednesday, August 24 the insider Chan Phillip P. bought $24,450. $14,640 worth of shares were bought by BATOR MICHAEL G. on Tuesday, June 7.
More notable recent Cytosorbents Corp (NASDAQ:CTSO) news were published by: Marketwatch.com which released: “Cytosorbents Corp.” on April 21, 2011, also Prnewswire.com with their article: “CytoSorbents to Present at the 2016 Rodman & Renshaw Annual Global Investment …” published on September 07, 2016, Prnewswire.com published: “CytoSorbents Expands CytoSorb® into Iran with Partner Arsak” on September 23, 2016. More interesting news about Cytosorbents Corp (NASDAQ:CTSO) were released by: Fool.com and their article: “Why Cytosorbents Corp Shares Burst Today” published on April 01, 2015 as well as Prnewswire.com‘s news article titled: “Terumo Cardiovascular Group and CytoSorbents Announce CytoSorb Cardiac Surgery …” with publication date: September 12, 2016.
CTSO Company Profile
CytoSorbents Corporation, incorporated on April 25, 2002, is a critical care focused immunotherapy company. The Firm is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. The Company’s CytoSorb is an extracorporeal cytokine filter and is designed to reduce the cytokine storm that causes inflammation, organ failure and death in common critical illnesses, such as sepsis, burn injury, trauma, lung injury and pancreatitis. In addition, CytoSorb is used in other inflammatory conditions, such as cardiac surgery, autoimmune disease flares, cancer, cytokine release syndrome in cancer immunotherapy and cancer cachexia.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.